ADPT — Stock Film
STOCK FILMSCENE 1/11ADPT · $24.20
Stock Expert AI presents
ADPT
Adaptive Biotechnologies Corporation
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Adaptive Biotechnologies Corporation. What it actually does.

Develops an immune medicine platform for the diagnosis and treatment of various diseases. Now — the numbers.

on the stock market since 2019
624 employees
$3.9B market value
WHERE DOES THE MONEY COME FROM?
51%Sequencing Revenue
Sequencing RevenueDevelopment Support Revenue 42%Development Revenue Regulatory Milestones 6%
51% of all revenue comes from a single line: Sequencing Revenue.

The biggest line carries real weight, but it doesn’t decide everything on its own.

Revenue last year:
$277M
The loss that same year:
$59.5M
For every $1 it earns, the company spends $1.2.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$227M
DEBT: $280.6M
At this pace, that money lasts about 3.8 years.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

THE PRICE TAG
MARKET VALUE / ANNUAL SALES
14×

This company is not turning a profit, so the market is pricing its sales instead: 14× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 45% of them.

Analysts' average target sits 1% above today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
65
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
19
very weak

Clearly below the class average.

VALUATION
45
weak

Clearly below the class average.

GROWTH
85
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
90
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 34% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 4 years, sales grew about 16% a year on average.

2
THE BRIGHT SIDE · 2/3
The product is selling

Sales run at $277.0M a year. A small number, but proof the product has real buyers.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/2
Running at a loss

A loss of $59.5M against $277.0M in annual sales.

2
THE RISKS · 2/2
A wildly swinging price

This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.

FINALE · THE GRADE
D
35 / 100 · MoonshotScore

On our five-subject report card, ADPT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ADPT is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film